Telix   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Melbourne Australia (2017)
Status: No NME R&D (2017)

Organization Overview

First Clinical Trial
2019
NCT03762759
First Marketed Drug
2021
Ga 68 PSMA-11 (Illuccix)
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TELIX | Telix International Pty Ltd | Telix Pharmaceutical

Active Ingredients

Marketed Drugs (1)

Key: Telix (0) Acquired (1)

Ga 68 PSMA-11 (Illuccix) (2021)

Drugs in Phase 3 Trials (3)

Key: Telix (1) Acquired (2)

177lu-dota-tlx591 (3 trials)

fluorocholine (1 trial)

Ga 68 PSMA-11 (Illuccix) (4 trials)

Drugs in Phase 2 Trials (3)

89zr-tlx250 (1 trial)

Fluciclovine (Axumin) (1 trial)

girentuximab (3 trials)

Drugs in Phase 1 Trials (5)

Key: Telix (4) Acquired (1)

153sm-dotmp (1 trial)

177lu-tlx250 (1 trial)

64cu-dota-tlx592 (1 trial)

Fluoroethyl-L-tyrosine (1 trial)

Peposertib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 11